Comparison of Liraglutide Versus Placebo in Weight Loss Maintenance in Obese Subjects: SCALE - Maintenance

• Status: Completed
• Trial end date: 2010-09-01
• Target enrollment: 0
• Participant gender: All

Summary

This trial is conducted in North America. The aim of this clinical trial is to evaluate the potential of liraglutide to maintain long term weight loss in obese non-diabetic subjects, as well as in overweight subjects who have medical problems such as hypertension (high blood pressure) or dyslipidaemia (an abnormal amount of lipids in the blood).

Trial has following trial periods: A 12-week run-in period (from week -12 to week 0) followed by a 56-week main trial period (weeks 0-56) and a 12-week follow-up period (weeks 56-68).

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novo Nordisk A/S
• Treatments: Liraglutide

Criteria

Inclusion Criteria:

• Body Mass Index (BMI) of either 30 kg/m^2 or more or BMI of less than 30 kg/m^2 to 27 kg/m^2 with presence of co-morbidities

• Stable body weight during the previous 3 months (less than 5 kg self-reported weight change)

• Previously undergone dietary weight loss and was not able to maintain reduced weight

Exclusion Criteria:

• Diagnosis of type 1 or type 2 diabetes

• Previous treatment with GLP-1 (glucagon-like peptide-1) receptor agonists (including liraglutide or exenatide), within the last 3 months

• Visit 1 thryoid stimulating hormone (TSH) outside of the range of 0.4-6.0 mIU/L

• History of chronic pancreatitis or idiopathic acute pancreatitis

• Obesity induced by other endocrinologic disorders (e.g., Cushing Syndrome)

• Current or history of treatment with medications that may cause significant weight gain for at least 3 months before this trial

• Current participation in an organized diet reduction program (or within the last 3 months)

• Currently using or have used within three months before this trial: pramlintide, sibutramine, orlistat, zonisamide, topiramate, phenteremine, or metformin

• Previous surgical treatment for obesity (excluding liposuction if performed more than one year before trial entry)

• History of major depressive disorder or a PHQ-9 (Patient Health Questionnaire-9) score of more than 15 within the last 2 years or history of other severe psychiatric disorders or diagnosis of an eating disorder

• Subjects with a lifetime history of a suicide attempt or history of any suicidal behavior within the past month before entry into the trial